Trial reportJournal of leukocyte biology2008
Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection.
Trial report in Journal of leukocyte biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells.Blood · 2011Trial
- Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.The Journal of infectious diseases · 2010Trial
- Metabolic engineering ofApplied and environmental microbiology · 2026Review
- Interferons in HIV-1 infection: mechanisms, antiviral potentials, and therapeutic challenges.Frontiers in immunology · 2025Review
- Association of polymorphisms in TLR3 and TLR7 genes with susceptibility to COVID-19 among Iranian population: a retrospective case-control study.Iranian journal of microbiology · 2024Article
- The BAFF-APRIL System in Cancer.Cancers · 2023Review
- Development and biological activity of long-acting recombinant human interferon-α2b.BMC biotechnology · 2020Article
- Effects of TLR7 Polymorphisms on the Susceptibility and Progression of HIV-1 Infection in Chinese MSM Population.Frontiers in immunology · 2020Article
- Review
- The Role of BAFF System Molecules in Host Response to Pathogens.Clinical microbiology reviews · 2017Review
- Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2014Article
- The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.Cytokine & growth factor reviews · 2013Review
- Interferon-α enhances 5'-deoxy-5-fluorouridine-induced apoptosis by ERK-dependant upregulation of thymidine phosphorylase.BioMed research international · 2013Article
- The type I interferon response during viral infections: a "SWOT" analysis.Reviews in medical virology · 2012Review
- How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?AIDS research and human retroviruses · 2012Review
- Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response.PLoS pathogens · 2011Article
- Association of TLR7 variants with AIDS-like disease and AIDS vaccine efficacy in rhesus macaques.PloS one · 2011Article
- Immune reconstitution of acquired immune deficiency syndrome.Chinese journal of integrative medicine · 2010Article
- Innate immune activation in primary HIV-1 infection.The Journal of infectious diseases · 2010Review
- A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages.Immunology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type I IFNs are needed for the production of antiviral antibodies in mice; whether they also stimulate primary antibody responses in vivo during human viral infections is unknown. This was assessed in patients acutely infected with HIV-1 and treated with IFN-alpha2b. Patients with acute HIV-1 infection were randomized to receive antiretroviral therapy alone (Group A, n=60) or combined for 14 weeks with pegylated-IFN-alpha2b (Group B, n=30). Emergence of anti-HIV antibodies was monitored during 32 weeks by Western blot (WB) analyses of serum samples. IFN-alpha2b treatment stimulated the production of anti-HIV antibodies. On Week 32, 19 weeks after the last IFN-alpha2b administration, there were 8.5 (6.5-10.0) HIV WB bands (median, interquartile range) in Group B and 7.0 (5.0-10.0) bands in Group A (P=0.054), and band intensities were stronger in Group B (P<0.05 for p18, p24, p34, p40, and p55 HIV antigens). IFN-alpha2b treatment also increased circulating concentrations of the B cell-activating factor of the TNF family (P<0.001) and ex vivo production of IL-12 (P<0.05), reflecting its effect on innate immune cells. Withdrawal of antiretroviral treatment on Week 36 resulted in a lower rebound of HIV replication in Group B than in Group A (P<0.05). Therefore, type I IFNs stimulate the emerging anti-HIV immune response in patients with acute HIV-1 infection, resulting in an improved control of HIV replication. Type I IFNs are thus critical in the development of efficient antiviral immune responses in humans, including the production of antiviral antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.